EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Adicet Bio, Inc. (0HX7) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Adicet Bio, Inc. $4.56, price $6.51, upside -30.0%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

GB · ISIN US0070022076

AB Thin data Sep 24, 2026

Adicet Bio, Inc.

0HX7 · LSE

Weak valuationQuality is weak on top of the rich price.

!Fair value $4.56 · Overvalued (−30.0%)
!Quality 39/100
!Mixed Growth (revenue YoY +156.8 %/yr)
!negative free cash flow
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Adicet Bio, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$339.12 $6.26 Fair Value $4.56 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $6.26 – $339.12 · fair‑value band $3.01 – $5.69 · the $6.51 price screens above the $4.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Adicet Bio in your weekly email

Every Wednesday you see whether Adicet Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

Show more

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Stock analysis

Adicet Bio, Inc. (0HX7) currently trades at $6.51, while our model-based Fair Value estimate is $4.56, 30.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $3.01 (bear) to $5.69 (bull), the price of $6.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality).

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Adicet Bio, Inc. reported revenue of $25.0M in FY2022 versus $8.2M in FY2018, a compound +32.2%/yr. Reported net income was −$117M in FY2025.

Key figures

Market cap $44.9M · EPS (TTM) $−1.05 · Return on equity −72.2% · Return on assets (EBIT) −47.0% · Free cash flow −$97.0M · Net cash $24.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

Fair Value models

Bear $3.01 Fair Value $4.56 Bull $5.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $2.84 $3.80 $5.68 51
All 1 models by family
Asset-Based
NCAV (Graham) $2.84 $3.80 $5.68 51

Open the full fair value analysis →

Notify me when 0HX7 reaches fair value

Put 0HX7 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 39/100

Of which business quality 40 · Market factors (momentum, volatility) 11

Profitability 0
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 91
Disciplined investing over empire-building
Low Volatility 8
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−485.3% (2018) → −290.3% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 0HX7, get fair value alerts →

Compare Adicet Bio, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Adicet Bio, Inc. · Fair Value
$4.56 −30%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Adicet Bio, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/0HX7

Frequently asked questions

Is Adicet Bio, Inc. (0HX7) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.56 versus a price of $6.51, about −30% upside (overvalued).
What is the fair value of 0HX7?
Our model-based fair value for Adicet Bio, Inc. is $4.56 (as of Sep 24, 2026), built from audited fundamentals. The current price: $6.51.
What is the quality score of 0HX7?
Adicet Bio, Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Adicet Bio, Inc. (0HX7)?
Our model-based price target is the fair value of $4.56 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $3.01, optimistic scenario $5.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Adicet Bio, Inc. stock forecast for 2026?
Our models put fair value at $4.56, about −30% upside versus a price of $6.51 (overvalued). Cautious scenario $3.01, optimistic scenario $5.69. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Adicet Bio, Inc. (0HX7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Adicet Bio, Inc. it is $4.56 per share (as of Sep 24, 2026), against a price of $6.51. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Adicet Bio, Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0HX7 trades above its calculated fair value: price $6.51, fair value $4.56, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0HX7?
No. The price is what the market pays today ($6.51); the fair value is what the company's own numbers justify ($4.56). For Adicet Bio, Inc. the two are $1.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Adicet Bio, Inc. worth?
The market values Adicet Bio, Inc. at about $44.9M (market capitalisation, as of Sep 24, 2026). Per share that is $6.51; our models calculate a fair value of $4.56 per share.
What do the bullish and bearish scenarios say about 0HX7?
Our models span a range for Adicet Bio, Inc.: cautious scenario $3.01, base $4.56, optimistic $5.69 per share (as of Sep 24, 2026, price $6.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0HX7 from its 52-week high?
Adicet Bio, Inc. trades at $6.51, about 61% below its 52-week high of $16.72 and 4% above the low of $6.26 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $4.56 is for.
Is Adicet Bio, Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price $6.51, calculated fair value $4.56 (−30%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0HX7 calculated?
We run Adicet Bio, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.56, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Adicet Bio, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Adicet Bio, Inc. (0HX7)?
The closing price on Oct 2, 2026 was $6.51. Our model-based fair value is $4.56, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Adicet Bio, Inc. right now?
The price sits above even our optimistic bull case ($5.69). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($3.01 to $5.69) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Adicet Bio, Inc.

How large is the market capitalisation of Adicet Bio, Inc. (0HX7)?
The market capitalisation of Adicet Bio, Inc. is $44.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Adicet Bio, Inc. (0HX7)?
Earnings per share at Adicet Bio, Inc. are $−1.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Adicet Bio, Inc. (0HX7)?
The return on equity (ROE) of Adicet Bio, Inc. is −72.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Adicet Bio, Inc. (0HX7)?
On an EBIT basis the return on assets of Adicet Bio, Inc. is −47.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Adicet Bio, Inc. (0HX7) generate?
The free cash flow of Adicet Bio, Inc. is −$97.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Adicet Bio, Inc. (0HX7) hold?
Adicet Bio, Inc. holds more cash than debt, $24.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Adicet Bio, Inc. in the live analysis

One click puts Adicet Bio, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.